Recent Updates
Recently added Catalysts

FKC876

Phase 1

Relapsed/Refractory Large B-cell Lymphoma | Small molecule | Oncology |Kairos Pharma, Ltd.|Last Updated: Jun 5, 2026

Target and mechanism

ModalitySmall molecule

Also known as FKC876 injection

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment12

FDA Designations

No designations recorded

Clinical trial landscape

FKC876 · 1 trial · 1 indication

Early Phase 1 1
NCT07606937A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.Relapsed/Refractory Large B-cell Lymphoma
RECRUITING12 Analytics
EARLY_PHASE1RECRUITING
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
Relapsed/Refractory Large B-cell Lymphoma
NCT0760693712
Unlock trial analytics

Study Endpoints

Primary Endpoints

Objective response rate (ORR)
Up to 24 months

Proportion of subjects with a best overall response of complete remission (CR) or partial remission (PR), as assessed by the Lugano 2014 classification (Cheson 2014)

Secondary Endpoints

Complete response rate (CRR)
Within 6 months,12 months, and 24 months after FKC876 infusion
Duriation of response (DOR)
Up to 24 months
Progression-frees survival (PFS)
Up to 24 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
FKC876 injectionEXPERIMENTAL -

Interventions

NameTypeDescription
FKC876 injectionDRUGCD19 CAR-T
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: 1. Age 18 years or older at the time of informed consent 2. Has signed the informed consent form (ICF) 3. Histologically proven large B-cell lymphoma 4. Relapsed or refractory disease after first-line chemoimmunotherapy 5. The subject has at least one measurable lesion on imagin...

Countries:China
Unlock Eligibility Criteria

Frequently asked questions about FKC876

What is FKC876 used for?

FKC876 is an investigational small molecule being developed for the treatment of relapsed/refractory Large B-cell Lymphoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.

Who makes FKC876?

FKC876 is being developed by Kairos Pharma, Ltd., a biopharmaceutical company listed on the stock exchange under the ticker symbol KAPA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.

What phase is FKC876 in?

FKC876 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The ongoing trial is an early-phase study designed to assess the drug's safety and preliminary efficacy in patients with relapsed/refractory Large B-cell Lymphoma.

What clinical trials is FKC876 in?

FKC876 is being studied in a Phase 1 clinical trial with the identifier NCT07606937. This trial is currently recruiting participants in China and is investigating the drug in patients with relapsed/refractory Large B-cell Lymphoma. The study is an uncontrolled, open-label trial with an expected enrollment of 12 participants.

Is FKC876 the same as FKC876 injection?

Yes, FKC876 is also known as FKC876 injection. Both names refer to the same investigational drug being developed by Kairos Pharma, Ltd. for the treatment of relapsed/refractory Large B-cell Lymphoma.